Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC [Yahoo! Finance]
Protara Therapeutics, Inc. (TARA)
Company Research
Source: Yahoo! Finance
TARA-002 demonstrated a complete response rate of 63% at three months in CIS-only patients in ongoing NMIBC program TARA-002 demonstrated a favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive data from three-month evaluable carcinoma in situ (CIS) patients treated across its ongoing clinical program of TARA-002, the Company's investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations. “These promising three-month results support the continued development of TARA-0
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Therapeutics, Inc. (NASDAQ: TARA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Here's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
- Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing [Yahoo! Finance]Yahoo! Finance
TARA
Earnings
- 3/13/24 - Beat
TARA
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- TARA's page on the SEC website